Other recommendations are CD45 (lymphoid malignancies), AE1/A3 pancytokeratin (cytokeratin for most carcinomas), S100 (melanoma), CD34 (vascular neoplasms), epithelial markers (EMA and CEA), chromogranin (neuroendocrine tumors), prostate-specific antigen (prostate cancer), thyroid transcription factor (for lung cancer), WT1 (ovarian carcinoma), CDX2 (intestinal carcinomas), and Hep Par1 (hepatocellular carcinoma) [7]. This evidence concerns the gene CD34 and carcinoma.